These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8324232)

  • 1. Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).
    Parks NJ; Kawakami TG; Avila MJ; White R; Cain GR; Raaka SD; Hornoff W; Fisher P; Moore P; Seibert JA
    Blood; 1993 Jul; 82(1):318-25. PubMed ID: 8324232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.
    Appelbaum FR; Brown PA; Sandmaier BM; Storb R; Fisher DR; Shulman HM; Graham TC; Schuening FG; Deeg HJ; Bianco JA
    Blood; 1992 Sep; 80(6):1608-13. PubMed ID: 1520886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
    Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H
    Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
    Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
    J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.
    Giralt S; Bensinger W; Goodman M; Podoloff D; Eary J; Wendt R; Alexanian R; Weber D; Maloney D; Holmberg L; Rajandran J; Breitz H; Ghalie R; Champlin R
    Blood; 2003 Oct; 102(7):2684-91. PubMed ID: 12730103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
    J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
    Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
    Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
    Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE
    J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.
    Bayouth JE; Macey DJ; Boyer AL; Champlin RE
    Med Phys; 1995 Jun; 22(6):743-53. PubMed ID: 7565363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary dosimetry of (166)Ho-propylene di-amino tetra (methy1enephosphonicacid) for human based on biodistribution data in rats.
    Zolghadri S; Yousefnia H; Jalilian AR; Shiri-Yekta Z; Maragheh MG
    J Cancer Res Ther; 2015; 11(4):862-7. PubMed ID: 26881532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical.
    Simón J; Frank RK; Crump DK; Erwin WD; Ueno NT; Wendt RE
    Nucl Med Biol; 2012 Aug; 39(6):770-6. PubMed ID: 22459336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.
    Das T; Chakraborty S; Sarma HD; Tandon P; Banerjee S; Venkatesh M; Pillai MR
    Nucl Med Biol; 2009 Jul; 36(5):561-8. PubMed ID: 19520297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
    Sohaib M; Ahmad M; Jehangir M; Perveen A
    Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
    Henriksen G; Bruland OS; Larsen RH
    Anticancer Res; 2004; 24(1):101-5. PubMed ID: 15015582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy.
    Hassfjell SP; Bruland OS; Hoff P
    Nucl Med Biol; 1997 Apr; 24(3):231-7. PubMed ID: 9228657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
    Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs.
    Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C
    J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation.
    Salek N; Vosoghi S; Arani SS; Samani AB; Mehrabi M; Maraghe MG
    Curr Radiopharm; 2018; 11(2):116-122. PubMed ID: 29651974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, purification and biodistribution of (205)Bi-DOTMP, visualizing bone deposition patterns with autoradiography.
    Hassfjell S; Ingebrigtsen K; Bruland ØS
    Nucl Med Biol; 2001 May; 28(4):425-33. PubMed ID: 11395316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.